On Sunday, November 9, Senate Majority Leader Thune announced that he had reached an agreement with a group of 8 Democratic senators and the White House on a deal to end the longest shutdown in U.S. history. On Monday, November 10, the Senate approved the government funding bill by a vote of 60-40, which sends the legislative package back to the House of Representatives.

To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.

To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.

President Donald Trump announced a series of agreements with Eli Lilly and Company and Novo Nordisk to offer Most-Favored-Nation (MFN) prices on two GLP-1 therapies, semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). This marks the fourth and fifth publicly announced agreements between the Trump administration and pharmaceutical manufacturers, joining earlier announcements with Pfizer, AstraZeneca, and EMD Serono. The manufacturers also agreed to cap prices for insulin products and other commonly prescribed diabetes medications.

Read the Journal of Managed Care + Specialty Pharmacy (JMCP) - November 2025 Issue

The Academy of Managed Care Pharmacy (AMCP), in partnership with the AMCP Research Institute, published the 2025 edition of its annual Access, Affordability, and Outcomes: The Value of Managed Care Pharmacy report, which provides an in-depth look at how managed care pharmacy practices improve patient health outcomes, control prescription drug spending, and promote affordability for millions of Americans.